We investigated the bone metabolism of 22 patients (median age 38 years) over 6 years after allogeneic bone marrow transplantation (BMT). Biplanar roentgenograms of the thoracic and lumbar spine were used to diagnose vertebral deformities caused by fractures. The actual bone mineral density (BMD) of the lumbar spine and the femoral neck were measured. Laboratory tests included calcium, phosphate, parathyroid hormone, a marker of bone resorption (beta-crosslaps, CTX), markers of bone formation (osteocalcin, bone-specific alkaline phosphatase), osteoprotegerin (OPG) -an antagonist of the osteoclast differentiation factor RANKL, and sex hormone status. One patient had a vertebral fracture. Seven patients (28%) had osteopenia in the lumbar spine while 12 patients (48%) had osteopenia in the femoral neck. Bone resorption was increased in nine patients (43%) and bone formation was increased in four patients (20%). BMT recipients had significantly increased serum levels of OPG (P ¼ 0.029). Three women (75%) and four men (25%) were hypogonadal. The data showed that BMD is reduced and bone metabolism is still disturbed more than 6 years after BMT. The RANKL/osteoprotegerin system appears to play an important role in the pathophysiology of late post transplantation osteoporosis.
metabolism; osteoprotegerin Organ transplantation is followed by bone loss and an increased incidence of fractures. 1 Recipients of heart, kidney, lung, and liver transplants have an increased risk of osteoporosis, 2-4 a systemic skeletal disease characterized by decreased bone mass and deterioration of the microarchitecture of bone tissue, as well as bone fragility and a susceptibility to fractures. 5 BMT recipients differ from solid organ transplantation recipients in terms of their underlying disease, organ dysfunction, age, and the median interval between diagnosis and transplantation; the interval is usually shorter for BMT. As a result, BMT recipients may receive less prior treatment that impairs bone metabolism, experience less restriction of their mobility, and have a more normal nutritional status. Additionally, BMT recipients generally receive less subsequent immunosuppressive therapy which may induce osteopenia. 6 Decreased bone mass may also result from graft-versus-host disease (GVHD) and its treatment. Glucocorticoids create a predisposition for osteopenia by depressing bone formation and increasing bone resorption. 7 Furthermore, the sex hormone deficiency induced by high-dose chemotherapy and total-body irradiation increases bone loss and commonly occurs in women after BMT. 8 Bone resorption markers are increased while bone formation markers are reduced or within normal limits after BMT. [9] [10] [11] The amount of bone loss within 1 year after transplantation varied between 2% for the lumbar spine 12 and 12% for the femoral neck. 11 At 5 years after allogeneic BMT, the lumbar spine BMD was within normal limits but the femoral neck BMD was decreased; osteopenia was present in 43% and osteoporosis in 7% of the patients. 13 The published literature reveals only one investigation with a follow-up of about 6 years after allogeneic BMT. 14 The study showed that seven of 26 patients had osteopenia, while no patient had osteoporosis. Bone mineral density (BMD) measurements about 4 years after autologous blood or marrow transplantation showed that 26 and 2% of patients had osteopenia and osteoporosis at the lumbar spine, respectively, and 46 and 8% of patients had osteopenia and osteoporosis at the femoral neck, respectively. 15 In contrast, Keilholz and co-workers 16 reported no reduction of BMD 5 years after autologous BMT. However, studies on autotransplants may not necessarily be applicable to allotransplant patients, since the latter require immunosuppressive therapy. Therefore, they might experience a greater reduction in their BMD than those who receive autotransplants.
Long-term data on bone loss after allogeneic BMT are scarce. Many bone-specific biochemical changes are not clearly understood. Serum levels of osteocalcin, a noncollagenous bone matrix protein, have been shown to reflect bone formation; whereas, those of CTX (crosslinked telopeptide of collagen I), which is released during the process of osteoclastic bone degradation, are a marker of bone resorption. Serum levels of osteoprotegerin (OPG) in BMT recipients have not been investigated so far; OPG is a glycoprotein expressed by osteoblasts. It belongs to the tumor necrosis factor receptor superfamily and regulates bone mass as a decoy receptor that competes with RANK (receptor activator of nuclear factor-kB) for the RANK ligand (RANKL), which inhibits osteoclast differentiation and activation. 17, 18 The purpose of the study was to evaluate bone metabolism, BMD, and vertebral fractures of long-term survivors of allogeneic bone marrow transplantation (BMT).
Patients and methods

Patients
In all, 22 patients (male/female: 18/4) who had undergone allogeneic BMT more than 5 years ago were included in the study. Characteristics of the patients are presented in Table 1 . The median age of the patients at the time of transplantation had been 38 years (range: 25-55 years); the patients were evaluated at a median of 73 months (range: 65-207 months) after BMT. No patient had regularly taken more than 60 g of alcohol per day, smoked more than 20 cigarettes per day, been immobile prior to BMT, or suffered from nonosteoporotic metabolic bone disease or rheumatoid arthritis.
All but three patients had HLA-identical donors. As a preparatory regimen before BMT, all patients received myeloablative-conditioning regimens, which consisted of fractionated total-body irradiation together with chemotherapy or chemotherapy. For GVHD prophylaxis all patients received cyclosporine A (CsA) and methotrexate according to the Seattle protocol. 19 The diagnosis of GVHD was made clinically and confirmed by appropriate biopsies. A total of 13 patients had to take corticosteroids for more than 1 month because of acute GVHD. Chronic GVHD occurred in eight patients and was treated according to a standard regimen. 20 At the time of evaluation all patients were in complete remission.
During the follow-up period no patient received bonespecific medication -calcium, vitamin D supplementation, or bisphosphonates -with the exception of two women with post BMT ovarian insufficiency who underwent hormone replacement therapy. At the time of the present investigation, no patient was on glucocorticoid therapy but three patients took CsA on a regular basis.
Written informed consent was obtained from all patients. The procedures were approved by the ethics committee of the University of Vienna and the General Hospital of Vienna.
X-ray, BMD measurement
Biplanar roentgenograms of the thoracic and lumbar spine were used to diagnose vertebral deformities caused by fractures. A semiquantitative method of fracture determination was applied. The actual BMD (BMD) of the lumbar spine (lumbar vertebrae L1-L4), femoral neck, trochanteric and intertrochanteric region, Ward's triangle, and total hip, were measured with dual energy X-ray absorptiometry using QDR 4500 (Hologic Inc., 590 Lincoln Street, Waltham, MA 02154, USA). All measurements were performed in accordance with the standard procedures recommended by the manufacturer. The X-ray results were taken into account for the analysis of BMD.
Laboratory tests
Blood samples were collected between 0800 and 1000; all analyses were performed from serum samples obtained after clotting and centrifugation of the blood. Calcium, phosphate, creatinine, urea, and total alkaline phosphatase were analyzed by a fully automated clinical chemistry system (Modular, Roche Diagnostics, Germany). Osteocalcin, beta-crosslaps (C-terminal telopeptide of type I collagen, CTX), parathyroid hormone, testosterone and 17-beta estradiol were measured by electrochemiluminescence immunoassays on Elecsys 2010 systems (Roche Diagnostics, Germany). Sex-hormone-binding globulin (SHBG) was quantified by a fluoroimmunoassay using an Auto-DELFIA analyzer (Wallac Oy, Finland). SHBG levels, testosterone or estradiol measurements, an average serum albumin content, and the respective association constants of the steroid hormones for SHBG and albumin, 21 were used to calculate the bioavailable hormone fractions. 22, 23 Concentrations of 25-hydroxy-vitamin D were determined by radioimmunoassay (DiaSorin, Stillwater, MN, USA), while bone-specific alkaline phosphatase was analyzed by an immunoadsorption test (Metra; Mountainview, CA, USA). OPG was measured using a highly sensitive polyclonal antibody-based sandwich enzyme immunoassay (Biomedica, Vienna, Austria) with intra-and interassay variabilities of 9 and 10%, respectively.
Definitions
According to the World Health Organization criteria for BMD, 24 we classified patients as normal (T score X1), presenting with osteopenia (T score oÀ1 and 4À2.5), or presenting with osteoporosis (T score pÀ2.5).
Data analysis
Descriptive statistics were calculated for all variables. All laboratory parameters were compared with established reference ranges except OPG. A Mann-Whitney test was used to compare OPG levels of BMT recipients with a group of age-and sex-matched controls (n ¼ 44) because a reference range for OPG has not been established so far. Wilcoxon's test was used to compare the T score of the hip with the T score of the femoral neck. Spearman's rank correlation coefficients were calculated to describe the correlation of biochemical parameters with BMD and the correlation of OPG with other bone-specific biochemical parameters.
The statistical software package SPSS 10.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis; P-values less than 0.05 were considered statistically significant.
Results
X-ray, BMD measurement
One male patient had a vertebral fracture (vertebra L4), which was diagnosed by X-ray. Overall, the median BMD at the lumbar spine was 1.0 [0.9; 1.1] g/cm 2 while the median T and Z scores were À0.5 [À1.3; 0.2] g/cm 2 and À0.4 [À1.1; 0.6], respectively. Seven patients (28%) had osteopenia and no patient had osteoporosis at the lumbar spine.
The median BMD at the femoral neck was 0.8 [0.7; 0.8] g/cm 2 ; the median T and Z scores were À1.5 [À1.7; À0.7] and À1.0 [À1.2; À0.3], respectively. In all, 12 patients (48%) had osteopenia at the femoral neck. Although the T scores of the femoral neck were significantly lower than those of the lumbar spine (P ¼ 0.002), no patient had osteoporosis at the femoral neck.
Group comparisons between patients who took corticosteroids on a regular basis for at least 1 month and those who had taken corticosteroids for less than a month showed similar BMDs for both groups. Patients who had undergone total body irradiation before BMT did not have a lower BMD than patients who had only received chemotherapy (data not shown).
Biochemistry
Three women (75%) had reduced estrogen and/or bioavailable estrogen. Two of the four women received hormone replacement therapy; one of them had a normal sex hormone status (at the time of the present investigation). Based on the bioavailable steroid hormone fractions, four men (25%) were rated as hypogonadal. No male patient received hormone replacement therapy. Table 2 shows the sex hormone status of male patients and the biochemical data of all patients.
Although the mean values of the markers of bone metabolism were within the normal range, some unusual features were noted. About one-fifth of the patients had increased total alkaline phosphatase (n ¼ 4) and parathyroid hormone levels (n ¼ 5). Vitamin D deficiency was observed in three patients (15%). The bone resorption marker beta-crosslaps was above the normal range in nine patients (43%), while the bone formation markers osteocalcin and bone-specific alkaline phosphatase were elevated in only three (15%) and four (20%) patients, respectively. Intergroup comparisons with age-and sex-matched controls showed that BMT recipients had significantly increased serum levels of OPG: the median values were 59.9 [44.4; 83.6] pg/ml for BMT recipients and 42 [29.5; 61.8] pg/ml for controls (P ¼ 0.029).
Comparison of the subgroup of three patients regularly taking CsA with 19 patients receiving no CsA treatment revealed no differences in serum OPG, but showed significantly higher values of the bone formation marker osteocalcin (P ¼ 0.011), 25-OH-vitamin D (P ¼ 0.042), and levels of beta-crosslaps (P ¼ 0.062) tended to have higher values in the former group.
Levels of the resorption marker beta-crosslaps correlated with the bone formation markers osteocalcin (r ¼ 0.574, P ¼ 0.008) and bone-specific alkaline phosphatase (r ¼ 0.544, P ¼ 0.013). Positive correlations were also observed between 25-OH-vitamin D and BMD of the lumbar spine (r ¼ 0.512, P ¼ 0.036) and, in men, between testosterone and BMD of the femoral neck (r ¼ 0.526, P ¼ 0.044). Additionally, a positive correlation was found between OPG and serum creatinine even when patients with elevated serum creatinine were excluded (r ¼ 0.697, P ¼ 0.003).
Discussion
This study was designed to investigate bone metabolism in allogeneic BMT survivors after more than 5 years post transplantation. The data clearly show that bone mass is reduced and bone metabolism is disturbed even longer than 6 years after transplantation. As seen in previous reports, [11] [12] [13] BMD of the femoral neck was more affected than BMD of the lumbar spine. The reason may be that corticosteroids mainly affect trabecular bone but are prescribed for a short time when GVHD occurs, whereas cyclosporine, which also affects cortical bone, 25 is part of the standard regimen for GVHD prophylaxis.
In contrast to most previous studies in BMT recipients, 10, 11, 13, 15 no patient in our cohort met the WHO criteria for osteoporosis whereas about one half of our BMT survivors had evidence of osteopenia. So far, only one investigation performed 75 months after allogeneic BMT 14 reported no patient with osteoporosis while 7/26 (27%) survivors had osteopenia. The median T and Z scores of the lumbar spine and the femoral neck in our patients were lower than those of BMT recipients investigated 6-156 months after transplantation, 13 and comparable with another group of BMT recipients investigated 2 years after transplantation. 11 The sharpest decline in BMD is known to occur during the first 6 months after BMT. 10, 26 The fact that no patient in our investigation and in the study performed by Kananen et al 14 had osteoporosis may have been due to the rather long follow-up period in the two studies. Most likely, the patients had a long period of time to recover from the bone-damaging interventions. However, in our investigation, more patients had evidence of osteopenia than in the study performed by Kananen et al.
14 The reason may be that a higher percentage of their patients used hormone replacement therapy while two female patients additionally received bisphosphonate therapy.
Although steroid treatment is known to be related to BMD values, we registered similar BMDs in patients who had taken corticosteroids for more than 1 month and those who had taken corticosteroids for less than 1 month. So far only Kananen et al 14 have investigated patients after a similar interval following BMT. They compared a group of patients who had required corticosteroids or CsA for more than 1 year with a group of patients who had not, and registered a more severe bone loss in the former. Glucocorticoid-induced osteoporosis is known to be reversible. 27, 28 However, nothing is known about the reversibility of CsA-induced osteoporosis. Thus, the more severe bone loss in the group treated for a long period of time (corticosteroids or CsA), observed by Kananen et al, 14 may have been due to the negative influence of CsA.
Biochemical analysis revealed increased bone resorption in 43% of patients, increased bone formation in 20% of patients, and hypovitaminosis D in 15% of patients. Normal bone metabolism depends on adequate serum levels of vitamin D. The compensatory response to vitamin D deficiency is a stimulation of parathyroid hormone secretion. This secondary hyperparathyroidism leads to an increase in bone turnover and bone loss. 29 The significant correlations between beta-crosslaps and osteocalcin or bone-specific alkaline phosphatase show that bone resorption and bone formation are rather closely coupled. The positive correlation between 25-OH-vitamin D and BMD underlines the importance of vitamin D in bone metabolism. Compared to heart transplantation recipients 30 BMT recipients had higher levels of 25-OH-vitamin D. The reason may be that BMT recipients are generally younger, more mobile, and less deconditioned than heart transplantation recipients. They probably spend more time outdoors and benefit from vitamin D synthesis due to sun exposure. A sex hormone deficiency might be additionally involved in disturbed bone turnover among at least some male BMT recipients. It is known for some time that testosterone deficiency, like estrogen deficiency, is associated with disorders of bone metabolism and accelerated bone loss. 31 In men, positive correlations were also found between testosterone and BMD of the femoral neck. Other studies 32, 33 established correlations between male sex hormones and the peripheral, but not the axial skeleton. Thus, it may be assumed that androgens have a greater impact on cortical than on trabecular bone.
BMT survivors had significantly increased serum levels of OPG vs age-and sex-matched controls. This finding differs from previous authors who investigated serum OPG levels in patients after solid organ transplantation. In patients after orthotopic liver transplantation who received higher doses of glucocorticoids and CsA than did BMT recipients, serum OPG levels were similar to those of healthy matched controls. 34 Heart transplantation recipi-ents who had received higher doses of immunosuppressive therapy than BMT and liver transplantation recipients, had reduced serum OPG levels. 35 This suggests a clinically relevant relationship between immunosuppressive therapy and OPG, which has been postulated from in vitro studies in which both glucocorticoids and CsA were shown to markedly downregulate OPG production in human osteoblastic cell lines. [36] [37] [38] Reduced BMD and partially increased serum levels of the beta-crosslaps, both reflecting increased bone resorption, apparently are in contrast to elevated OPG. The detection system for OPG measures total OPG, that is, it cannot discriminate between free OPG and OPG as a complex with RANKL (RANK ligand). Thus, elevated levels of OPG may be due to an increase in free OPG, an increase in OPG-RANKL complexes, or both. 39 Since a large number of BMT recipients had evidence of increased bone resorption, we assume that the most likely explanation for the high OPG levels is an augmentation of OPG-RANKL complexes.
The majority of BMT candidates previously had received cyclophosphamide. A follow-up of long-term survivors of highly malignant osteosarcoma who had received high-dose chemotherapy including cyclophosphamide showed that osteoporosis was a common occurrence in these patients. 40 Thus, besides immunosuppressive therapy, the myeloablative regimen before BMT may be responsible for the decreased bone mass in long-term survivors of BMT.
Patients on CsA treatment had elevated serum osteocalcin levels and tended to have higher serum beta-crosslaps than patients not currently taking CsA. Thus, it seems that increased bone turnover, which is suggested by biochemical analysis of BMT recipients, is mainly present in patients regularly taking CsA. We previously showed that cyclosporine seems to be at least partly responsible for bone loss long after transplantation in HTX recipients as well. 30 From the age of about 35 onwards, all individuals experience loss of bone mass. Osteoporosis may be caused by a lower peak bone mass or accelerated bone loss. Patients who have to undergo BMT and bone-damaging treatment are at greater risk for osteoporosis. In the short term, osteoporosis seems trivial compared with a diagnosis of cancer. Yet, even for those cured of their disease, the decreased BMD may contribute to chronic morbidity and cause the patients to require assistance in activities of daily living.
One vertebral fracture occurred during the follow-up period of the present study. This shows that (a) the bone metabolism of BMT recipients is disturbed, and (b) fractures do occur, but only in a small percentage of patients. However, with advancing time after BMT, BMD values tend to increase.
The limitations of the present study are its cross-sectional design and the small number of patients, which do not allow definite characterization of the main factors contributing to the long-term regulation of bone metabolism in BMT recipients.
Our study implies that, more than 6 years after BMT, BMD is still reduced. In contrast to many studies we observed no osteoporosis, which was most likely due to the long follow-up period during which the patients were able to regain some bone mass. Disturbances in bone metabolism may have been caused by the bone-damaging pretransplantation therapy itself, the resulting hypogonadism, or post transplantation immunosuppressive therapy. The RANKL/OPG system appears to play an important role in the pathophysiology of late post transplantation osteoporosis.
